Stockreport

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology, Inc.  (PYXS) 
PDF BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) the [Read more]